These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 7490884)
1. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884 [TBL] [Abstract][Full Text] [Related]
2. Detection of autocrine motility factor in urine as a marker of bladder cancer. Guirguis R; Schiffmann E; Liu B; Birkbeck D; Engel J; Liotta L J Natl Cancer Inst; 1988 Oct; 80(15):1203-11. PubMed ID: 3138430 [TBL] [Abstract][Full Text] [Related]
3. Motility- and adhesion factors in bladder carcinoma. Otto T; Goepel M; Enzwi SM; Meyer-Schwickerath M; Rübben H Investig Urol (Berl); 1994; 5():80-4. PubMed ID: 7719326 [No Abstract] [Full Text] [Related]
4. [Principles of tumor invasion and metastasis]. Otto T; Goepel M; Recker F; Rübben H Urologe A; 1995 May; 34(3):208-11. PubMed ID: 7610514 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796 [TBL] [Abstract][Full Text] [Related]
6. Urine laminin P1 assessment discriminates between invasive and noninvasive urothelial cell carcinoma of the bladder. Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW Urol Int; 1993; 51(4):204-8. PubMed ID: 8266611 [TBL] [Abstract][Full Text] [Related]
7. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Jamshidian H; Kor K; Djalali M Urol J; 2008; 5(4):243-7. PubMed ID: 19101898 [TBL] [Abstract][Full Text] [Related]
9. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder. Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881 [TBL] [Abstract][Full Text] [Related]
10. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. Wang W; Yang LY; Yang ZL; Peng JX; Yang JQ Dig Dis Sci; 2007 Mar; 52(3):770-5. PubMed ID: 17265125 [TBL] [Abstract][Full Text] [Related]
11. [Urinary cytology in cases of bladder cancer: a critical evaluation]. Rathert P Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033 [TBL] [Abstract][Full Text] [Related]
12. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629 [TBL] [Abstract][Full Text] [Related]
13. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma. Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of urinary soluble Fas in screening for bladder cancer. Srivastava AK; Singh PK; Singh D; Dalela D; Rath SK; Bhatt ML Asia Pac J Clin Oncol; 2016 Jun; 12(2):e215-21. PubMed ID: 24576318 [TBL] [Abstract][Full Text] [Related]
15. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219 [TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510 [TBL] [Abstract][Full Text] [Related]
17. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Vlahou A; Schellhammer PF; Mendrinos S; Patel K; Kondylis FI; Gong L; Nasim S; Wright GL Am J Pathol; 2001 Apr; 158(4):1491-502. PubMed ID: 11290567 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191 [TBL] [Abstract][Full Text] [Related]
19. [Non-invasive urinary diagnosis of bladder cancer. What do we know?]. Kausch I; Böhle A Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034 [TBL] [Abstract][Full Text] [Related]
20. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Bonner RB; Hemstreet GP; Fradet Y; Rao JY; Min KW; Hurst RE Cancer; 1993 Oct; 72(8):2461-9. PubMed ID: 8402463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]